Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials

Yasmin Essaji, Flavio G. Rocha

    Research output: Contribution to journalReview articlepeer-review

    1 Scopus citations


    Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long-term survival. In the mid-1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5-fluorouracil-based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.

    Original languageEnglish (US)
    Pages (from-to)1467-1474
    Number of pages8
    JournalJournal of surgical oncology
    Issue number6
    StatePublished - May 1 2021


    • adjuvant chemoradiation
    • adjuvant chemotherapy
    • evidence-based medicine
    • pancreatic cancer

    ASJC Scopus subject areas

    • Surgery
    • Oncology


    Dive into the research topics of 'Seminars in surgical oncology—Pancreas cancer adjuvant therapy trials'. Together they form a unique fingerprint.

    Cite this